Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Third party research

IRLAB Therapeutics: IRL757 starts Ph 1b - ABG

IRLAB Therapeutics

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Ph 1b in PD-apathy starts in H2'25
Safety and early efficacy the main goals
Comes with USD 4.5m cash injection from MSRD


Ph 1b in PD-apathy with MSRD

Today IRLAB Therapeutics announced the initiation of a Ph 1b study with the apathy candidate IRL757. The first patient in (FPI) is planned for H2'25 and IRLAB's collaboration partner MSRD will finance the startup cost through an initial payment of USD 4.5m to be booked still in Q1. The decision builds on the collaboration agreement signed with MSRD in May'24.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.